Michael Kragh
13Patents
3h-index
27Co-inventors
60Inventor score
Filing activity: Feb 8, 2001 → Jun 7, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10058610B2 | Methods for treating cancer by administering humanized pan-HER antibody compositions | Chemistry; Metallurgy | 8 | Active |
| US9527913B2 | Humanized pan-HER antibody compositions | Chemistry; Metallurgy | 3 | Active |
| US9155802B2 | Pan-HER antibody composition | Chemistry; Metallurgy | 3 | Active |
| US11034765B2 | Anti-PD-1 antibodies and compositions | Chemistry; Metallurgy | 3 | Active |
| US11390676B2 | Anti-LAG-3 antibodies and compositions | Chemistry; Metallurgy | 2 | Active |
| US10221246B2 | Pan-HER antibody composition | Chemistry; Metallurgy | 2 | Active |
| US8663640B2 | Methods using recombinant anti-epidermal growth factor receptor antibody compositions | Chemistry; Metallurgy | 2 | Active |
| US11390674B2 | Anti-TIM-3 antibodies and compositions | Chemistry; Metallurgy | 1 | Active |
| US6701171B2 | Method and apparatus for non-invasive detection of angiogenic and anti-angiogenic activity in living tissue | Physics | 1 | Expired |
| US11834503B2 | Anti-lag-3 antibodies and compositions | Chemistry; Metallurgy | 0 | Active |
| US10450376B2 | Anti-MET antibodies and compositions | Chemistry; Metallurgy | 0 | Active |
| US12030942B2 | Anti-PD-1 antibodies and compositions | Chemistry; Metallurgy | 0 | Active |
| US11939380B2 | Combination therapies targeting PD-1, TIM-3, and LAG-3 | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.